


Thoracic Medicine

Volume 40 • Number 3 • September 2025



| The Official Journal of



Taiwan Society of
Pulmonary and Critical
Care Medicine



Taiwan Society of Sleep
Medicine



Taiwan Society for
Respiratory Therapy



Taiwan Society of
Tuberculosis and Lung
Diseases

Thoracic Medicine

The Official Journal of
Taiwan Society of Pulmonary and Critical Care Medicine
Taiwan Society for Respiratory Therapy
Taiwan Society of Sleep Medicine
Taiwan Society of Tuberculosis and Lung Diseases

Publisher

**Yuh-Min Chen, M.D.,
Ph.D., President**

*Taiwan Society of
Pulmonary and Critical
Care Medicine*

**Shih-Hsing Yang Ph.D.,
RRT, President**

*Taiwan Society for
Respiratory Therapy*

**Jann-Yuan Wang M.D.,
Ph.D., President**

*Taiwan Society of
Tuberculosis and Lung
Diseases*

**Li-Pang Chuang, M.D.,
President**

*Taiwan Society of Sleep
Medicine*

Editor-in-Chief

**Kang-Yun Lee, M.D.,
Ph.D., Professor**

*Taipei Medical University-
Shuang Ho Hospital, Taiwan*

Deputy Editors-in-Chief

Po-Chun Lo, M.D.,

*Department of Internal
Medicine, Taoyuan General
Hospital, Ministry of Health
and Welfare, Taoyuan,
Taiwan*

Editorial Board

Section of Pulmonary and Critical Care Medicine

Jin-Yuan Shih, M.D., Professor
*National Taiwan University
Hospital, Taiwan*

**Gee-Chen Chang, M.D.,
Professor**

*Chung Shan Medical University
Hospital, Taiwan*

**Jann-Yuan Wang M.D., Ph.D.,
Professor**

*National Taiwan University
Hospital, Taiwan*

**Kuang-Yao Yang, M.D., Ph.D.,
Professor**

*Taipei Veterans General
Hospital, Taiwan*

**Chi-Li Chung, M.D., Ph.D.,
Associate Professor**

*Taipei Medical University
Hospital, Taiwan*

**Chien-Chung Lin, M.D., Ph.D.,
Professor**

*Department of Internal Medicine,
College of medicine, National
Cheng Kung University, Taiwan*

Section of Respiratory Therapy

**Hui-Ling Lin, Ph.D. RRT, RN,
FAARC, Professor**

Chang Gung University, Taiwan

**I-Chun Chuang, Ph.D.,
Associate Professor**

*Kaohsiung Medical University
College of Medicine, Taiwan*

**Chun-Chun Hsu, Ph.D.,
Associate Professor**

Taipei Medical University

**Shih-Hsing Yang, Ph.D.,
Associate Professor**

*Fu Jen Catholic University,
Taiwan*

**Chin-Jung Liu, Ph.D.,
Associate Professor**

*China Medical University
Hospital, Taichung, Taiwan*

Section of Tuberculosis and Lung Diseases

**Jann-Yuan Wang, M.D.,
Professor**

*National Taiwan University
Hospital, Taiwan*

**Chen-Yuan Chiang, M.D.,
Associate Professor**

*Taipei Municipal Wanfang
Hospital, Taiwan*

Ming-Chi Yu, M.D., Professor

*Taipei Municipal Wanfang
Hospital, Taiwan*

**Yi-Wen Huang, M.D.,
Professor**

*Changhua Hospital, Ministry
of Health & Welfare, Taiwan*

Wei-Juin Su, M.D., Professor

*Taipei Veterans General
Hospital, Taiwan*

Section of Sleep Medicine

**Li-Ang Lee, M.D.,
Associate Professor**

*Linkou Chang Gung Memorial
Hospital, Taiwan*

**Hsin-Chien Lee, M.D.,
Associate Professor**

*Taipei Medical University-
Shuang-Ho Hospital, Taiwan*

**Li-Pang Chuang, M.D.,
Associate Professor**

*Linkou Chang Gung Memorial
Hospital, Taiwan*

**Li-Pang Chuang, M.D.,
Assistant Professor**

*Linkou Chang Gung Memorial
Hospital, Taiwan*

International Editorial Board

**Charles L. Daley, M.D.,
Professor**

*National Jewish Health Center,
Colorado, USA*

**Chi-Chiu Leung, MBBS, FFPH,
FCCP, Professor**

*Stanley Ho Centre for
Emerging Infectious Diseases,
Hong Kong, China*

**Daniel D. Rowley, MSc,
RRT-ACCS, RRT-NPS,
RPFT, FAARC**

*University of Virginia Medical
Center, Charlottesville, Virginia,
U.S.A.*

Fang Han, M.D., Professor

*Peking University People's
Hospital Beijing, China*

Liang Xu, MD.

*Director of Wuhan Wuchang
Hospital Professor of Wuhan
University of Science and
Technology Wuhan, China*

**J. Brady Scott, Ph.D., RRT-
ACCS, AE-C, FAARC, FCCP,
Professor**

*Rush University, Chicago,
Illinois, USA*

**Kazuhiro Ito, Ph.D., DVM,
Honorary Professor**

Imperial College London, UK

**Kazuo Chin (HWA BOO JIN),
M.D., Professor**

*Graduate School of Medicine,
Kyoto University*

**Masaki Nakane, M.D., Ph.D.,
Professor**

*Yamagata University Hospital,
Japan*

**Naricha Chirakalwasan, M.D.,
FAASM, FAPSR, Associate
Professor**

*Faculty of Medicine,
Chulalongkorn University,
Thailand*

**Petros C. Karakousis, M.D.,
Professor**

*The Johns Hopkins University
School of Medicine, USA*

Thoracic Medicine

The Official Journal of
Taiwan Society of Pulmonary and Critical Care Medicine
Taiwan Society for Respiratory Therapy
Taiwan Society of Sleep Medicine
Taiwan Society of Tuberculosis and Lung Diseases

Volume **40**

Number **3**

September 2025

CONTENTS

Original Articles

The Association Between Metformin Use and Outcomes of Hospitalized COVID-19

Patients 194~201

Chen-Yi Lin, Hsin-Pei Chung, Yen-Hsiang Tang, Chun-Yen Chen, Chao-Hsien Chen, Wen-Kuei Chang, Kuan-Chih Kuo,
Yen-Ting Chen, Jou-Chun Wu, Chang-Yi Lin, Chieh-Jen Wang

Prognosis of EGFR-mutated Non-small Cell Lung Cancer Patients with

Intra-abdominal Metastases 202~212

Hao-Ming Wu, Chi-Tsun Chiu, Jia-Shiuan Ju, Ping-Chih Hsu, Li-Chung Chiu, Horng-Chyuan Lin, Cheng-Ta Yang, How-Wen Ko

Clinical Features of Thoracic Actinomyces: Experience with 16 Cases at a Regional Hospital in Southern Taiwan 213~221

Wen-Ren Lin, Hui-Yuan Hsiao, Kuo-An Chu, Shoa-Lin Lin

Case Reports

Subclavian Artery Aneurysm Mimicking a Lung Mass: A Case Report and

Literature Review 222~228

Yu-Ting Lin, Shan-Yao Yang, I-Ming Chen, Chia-I Shen

Lethal Complication of Post-air-way Stenting to Trachea and Left Main Bronchus:

A Case Report 229~232

Kuan-Hsun Lin, Tsai-Wang Huang

Pulmonary Cryptococcosis Coexisting with Metastatic Pulmonary Tumors:

A Case Report 233~238

Chen-Chuan Hsu, Chiung-Hsin Chang, Tai-Di Chen, Yu-Hsiu Chen, Jia-Shiuan Ju, How-Wen Ko

The Association Between Metformin Use and Outcomes of Hospitalized COVID-19 Patients

Chen-Yi Lin¹, Hsin-Pei Chung^{1,3}, Yen-Hsiang Tang^{2,3}, Chun-Yen Chen^{3,4}
 Chao-Hsien Chen^{1,3}, Wen-Kuei Chang^{1,3}, Kuan-Chih Kuo^{1,3}, Yen-Ting Chen^{1,3}
 Jou-Chun Wu^{1,3}, Chang-Yi Lin^{1,3}, Chieh-Jen Wang^{1,3,*}

Background: Metformin is a widely prescribed medication for type 2 diabetes; however, therapeutic effects beyond glucose control have been reported. Recent studies have suggested its potential in alleviating symptoms of post-COVID-19 condition (long COVID), and possibly shortening the duration of the disease. We conducted this study to investigate whether metformin use could improve the outcomes of hospitalized COVID-19 patients.

Methods: We included patients diagnosed with COVID-19 infection at MacKay Memorial Hospital from May to June 2021. We categorized the patients into metformin and non-metformin use groups, regardless of their diabetes mellitus status.

Results: A total of 285 patients were included. After propensity score matching, 82 patients were enrolled for analysis, including 41 patients in each group. Cox proportional hazards analysis showed that mortality was not related to metformin use (adjusted hazard ratio [aHR]: 0.67, 95% confidence interval [CI]: 0.05-9.2, $p=0.76$) or duration of metformin use (aHR: 0.91, 95% CI: 0.74-1.13, $p=0.40$). However, patients with a longer duration of metformin use had a higher risk of receiving invasive mechanical ventilation support (aHR: 1.08, 95% CI: 1.03-1.13, $p=0.003$).

Conclusion: Our findings showed that mortality was not significantly associated with metformin use or its duration. However, patients with a longer duration of metformin use appeared to have a higher risk of requiring invasive mechanical ventilation support. Consequently, the duration of metformin use may be linked to the progression of COVID-19. Further studies are warranted to clarify the relevance of metformin use in the treatment of COVID-19. (*Thorac Med* 2025; 40: 194-201)

Key words: Metformin, COVID-19, mortality, mechanical ventilation

¹Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, Taipei City, Taiwan.

²Department of Critical Care Medicine, MacKay Memorial Hospital, Taipei, Taiwan. ³Department of Medicine, MacKay Memorial College, New Taipei City, Taiwan. ⁴Division of Cardiology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.

Address reprint requests to: Dr. Chieh-Jen Wang, Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd., Zhongshan Dist., Taipei City, 104, Taiwan.

Prognosis of *EGFR*-mutated Non-small Cell Lung Cancer Patients with Intra-abdominal Metastases

Hao-Ming Wu¹, Chi-Tsun Chiu², Jia-Shiuan Ju¹, Ping-Chih Hsu^{1,3}, Li-Chung Chiu^{1,3}
Horng-Chyuan Lin^{1,3}, Cheng-Ta Yang^{1,4,5}, How-Wen Ko^{1,3}

Background: Non-small cell lung cancer (NSCLC) patients generally have a poor prognosis with distant metastasis. Studies have found that NSCLC patients with epidermal growth factor receptor (*EGFR*) mutations exhibit a higher incidence of brain and bone involvement, which worsens prognosis. However, little is known about the outcomes of *EGFR*-mutated patients with intra-abdominal metastasis.

Materials and Methods: This retrospective study included 383 metastatic NSCLC patients with an *EGFR* mutation who received first-line gefitinib, erlotinib or afatinib at our hospital between January 2016 and December 2017.

Results: Ninety-eight patients (26%) had intra-abdominal metastasis, including liver (47), adrenal/renal (42), and abdominal lymph node/spleen (31) metastasis. In patients with intra-abdominal metastasis, overall survival (OS) (median, 17.5 vs. 32.7 months; $p < 0.001$) and progression-free survival (PFS) (median, 9.15 vs. 14.7 months; $p < 0.001$) were significantly shorter than in those without intra-abdominal metastasis. Compared to *EGFR*-mutated patients with only intra-thoracic metastasis (stage M1a), patients with intra-abdominal metastasis had the worse OS (hazard ratio (HR), 2.894; 95% confidence interval (CI), 2.051–4.082; $p < 0.001$), with the most severe reduction in OS in patients with adrenal/renal metastasis (HR, 5.646; 95% CI, 3.309–9.633; $p < 0.001$). No significant differences were observed in prognosis and response to first-line *EGFR*-TKIs between patients with an L858R mutation and those with an exon 19 deletion. The frequency of acquired T790M mutations was lower in patients with intra-abdominal metastases than in those without, but without statistical significance.

Conclusion: Intra-abdominal metastasis in *EGFR*-mutated NSCLC patients was associated with poor survival, with the worst outcomes in those with adrenal/renal metastasis. (*Thorac Med* 2025; 40: 202-212)

Key words: Intra-abdominal metastasis, liver, adrenal, *EGFR*, NSCLC

¹Division of Thoracic Medicine, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan. ²Institute of European and American Studies, Academia Sinica, Taiwan. ³Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan. ⁴Department of Internal Medicine, Taoyuan Chang Gung Memorial Hospital, Taoyuan City 33378, Taiwan. ⁵Department of Respiratory Therapy, College of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan.

Address reprint requests to: Dr. How-Wen Ko, Department of Thoracic Medicine, Chang Gung Memorial Hospital, No. 5, Fuxing St., Guishan Dist., Taoyuan 33305, Taiwan.

Clinical Features of Thoracic Actinomycosis: Experience with 16 Cases at a Regional Hospital in Southern Taiwan

Wen-Ren Lin¹, Hui-Yuan Hsiao², Kuo-An Chu^{1,3}, Shoa-Lin Lin²

Background: Thoracic actinomycosis is a rare bacterial infection. This study aimed to enhance clinicians' knowledge of this rare condition in clinical practice.

Materials and Methods: We retrospectively analyzed 16 patients with histopathologically confirmed thoracic actinomycosis treated between 1995 and 2012.

Results: Almost all patients had a cough (87.5%, 14/16) with hemoptysis (75%, 12/16) or sputum (56.3%, 9/16). The radiographic picture included a peripheral mass or consolidation (68.8%, 11/16), pleuritis with or without effusion (43.8%, 7/16), and mediastinal lymphadenopathy (37.5%, 6/16). Five out of the 16 (31.3%) patients were diagnosed non-surgically, received medical therapy alone, and had excellent outcomes. Two patients exhibited endobronchial involvement associated with foreign bodies. All 16 patients responded well to penicillin, followed by ampicillin (8/16), amoxicillin (3/16), clindamycin (1/16), minocycline (2/16), erythromycin (1/16), or no antibiotic treatment (1/16). The patients had a good prognosis with no relapse.

Conclusion: Foreign body-induced endobronchial infection responded favorably to foreign body removal and a short course of antibiotics. Medical therapy alone is often sufficient for a cure. When encountering this condition, the pulmonologist should consider the probability of actinomycosis, then diagnose the condition least invasively, thereby avoiding unwarranted surgery. (*Thorac Med* 2025; 40: 213-221)

Key words: actinomycosis; bronchoscopy; pathology; pulmonary; thoracic disease; treatment

¹Division of Chest Medicine, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. ²Division of Chest Medicine, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung, Taiwan. ³National Yang-Ming University School of Medicine, Taipei, Taiwan.

Address reprint requests to: Dr. Hui-Yuan Hsiao, Division of Chest Medicine, Department of Internal Medicine, Yuan's General Hospital, No. 162, Chenggong 1st Road, Kaohsiung City 802, Taiwan.

Subclavian Artery Aneurysm Mimicking a Lung Mass: A Case Report and Literature Review

Yu-Ting Lin¹, Shan-Yao Yang², I-Ming Chen^{3,4}, Chia-I Shen^{1,4,5}

Subclavian artery aneurysm is a rare vascular disorder that can mimic lung masses in imaging studies, often leading to diagnostic challenges. We reported the case of a 70-year-old man who presented with hemoptysis and progressive left-side chest pain. Initial imaging without contrast suggested a left upper lobe lung mass with mediastinal invasion. Despite multiple diagnostic attempts, no malignancy was identified. Further evaluation with Doppler ultrasound and contrast-enhanced computed tomography revealed a left subclavian artery aneurysm, with a characteristic "yin-yang" sign detected by the Doppler ultrasound. The patient underwent successful endovascular stent placement and showed clinical improvement. In this case report, we reviewed the possible presentation, diagnostic approach, and management strategies of this rare disease. We also highlighted how multi-modality imaging techniques—such as ultrasonography—can offer enhanced diagnostic value. (*Thorac Med* 2025; 40: 222-228)

Key words: Subclavian artery aneurysm, yin-yang sign

¹Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. ²Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. ³Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan. ⁴School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. ⁵Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Address reprint requests to: Dr. Chia-I Shen, Department of Chest Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan.

Lethal Complication of Post-air-way Stenting to Trachea and Left Main Bronchus: A Case Report

Kuan-sun Lin¹, Tsai-Wang Huang¹

Insertion of a metallic airway stent is a valuable method for the treatment of benign and malignant airway stenosis and a tracheal-esophageal fistula. Although stenting for airway stenosis has become widely used, with favorable outcomes, several complications after stenting, such as migration, a tendency for stent fracture, and ingrowth of the tumor or granulation tissue in the stent have occurred. Very few of these reports have described the complications of post-stenting pneumothorax. We report the case of a patient diagnosed with squamous cell carcinoma of the esophagus, complicated by a tracheal-esophageal fistula and treated with a tracheal stent or bronchial stent, who developed post-stenting pneumothorax. Esophageal cancer led to the lethal complication of the tracheal-esophageal fistula, which was complicated in handling. Although tracheal and left main bronchial airway stent placement remains a high risk, careful selection of stents (Y-stents) and placement location can reduce postoperative fatal complications. (*Thorac Med* 2025; 40: 229-232)

Key words: airway stent, complication, pneumothorax, squamous cell carcinoma of the esophagus

¹Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.

Address reprint requests to: Dr. Tsai-Wang Huang, Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital 325, Cheng-Kung Road, 2nd section, Taipei 114, Taiwan, Republic of China.

Pulmonary Cryptococcosis Coexisting with Metastatic Pulmonary Tumors: A Case Report

Chen-Chuan Hsu¹, Chiung-Hsin Chang¹, Tai-Di Chen², Yu-Hsiu Chen²,
Jia-Shiuan Ju¹, How-Wen Ko¹

Pulmonary cryptococcosis (PC) is a common disease caused by *Cryptococcus neoformans* infection. Differentiating PC from pulmonary malignancy in the setting of multiple pulmonary lesions can be challenging. We reported a patient with biopsy-proven PC and metastatic pulmonary tumors, and discuss the clinical reasoning behind the managing of multiple pulmonary nodules. (***Thorac Med* 2025; 40: 233-238**)

Key words: pulmonary cryptococcosis, lung metastasis, treatment response, multiple pulmonary nodules

¹Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. ²Department of Anatomic Pathology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Address reprint requests to: Dr. How-Wen Ko, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan No. 5, Fuxing St., Guishan Dist., Taoyuan, Taiwan.